Index

Figures and tables are indicated by ‘f’ and ‘t’ respectively

- airway hyper-responsiveness (AHR)
  - bronchial provocation tests, 99, 101
  - ICS, 102
- amyloid myopathy, 87–88
- asthma
  - bronchial provocation test, 23, 108, 109, 112
  - corticosteroid, 7–8
  - exercise-induced, 106, 107, 113, 114, 115
  - obstructive ventilatory defect, 5
  - poor quality test, 122–123, 134, 135
  - spirometry, 26, 32, 33
  - static lung volume, 44–45
  - Tl CO, 68–69, 71
- atopic asthma, 110
- atrial fibrillation, 151–153

BD. See bronchodilator (BD)
- bi-basal pneumonia, 156–157
- breathlessness, 96–97, 139

- bronchial provocation tests
  - airway responsiveness, 100
  - asthma, 101, 104f, 107–110
  - chronic cough, 106–107
  - clinical context, indirect challenges, 102, 104f
  - comparisons, 103

- direct challenges, 99
  - evaluation, 101–103f
  - exercise-associated asthma, 113, 114, 115
  - inhalation challenges, 100
  - interpretation, 101–104
  - medications and foods to avoid, 100f
  - methacholine challenges, 101
  - nocturnal cough, wheeze on exertion, 111
  - paroxysmal shortness of breath, 105–106
  - physical challenges, 100
  - provoking dose (PD), 100
  - sensitivity/specificity data, 101–102, 104f
  - severity scales, 102
  - test quality, 101
  - types, 99
  - wheeze on exertion, 112

- bronchiectasis, 5, 25, 72, 142–145, 153–155
- bronchoconstriction, 99, 101, 114, 135
- bronchodilator (BD)
  - AHR, 101
  - asthma, 23
  - baseline spirometry, 18
bronchodilator (BD) (continued)
reversibility, 99
spirometry before and after, 18

carbon monoxide diffusing capacity
(DLCO), 53
carbon monoxide transfer factor
(TlCO)
alveolar PO2, 57
alveolar volume, 57
amiodarone, 73–74
application, 60–61
asthma, 71–72
bronchial provocation test, 68–69
carboxyhaemoglobin (COHb), 56
comparison to previous results, 60
congestive cardiac failure, 66–67
COPD, emphysema, 63–64
DLCO, 53
factors affecting, 55, 56t
haemoglobin (Hb), 55–56
Hodgkin’s lymphoma, 77–78
interstitial lung disease, 70–71,
75–76
limits, normal range, 58–59, 59t
obesity hypoventilation syndrome, 
64–65
parameters, 53, 54, 58
pulmonary capillary blood
volume, 57
single breath carbon monoxide
transfer factor, 53, 54t
test quality, 54–55
TLC, 53
transfer coefficient, KCO, 57, 59–60
chronic cough, 106–107, 124–129
chronic obstructive pulmonary
disease (COPD), 24–25, 28, 42,
50, 94–95
coefficient of repeatability (CR), 5–8
COPD. See chronic obstructive 
pulmonary disease (COPD)
cough and dyspnoea, 92–93
CR. See coefficient of repeatability 
(CR)
diaphragm paralysis, 84–85
dyspnoea on exertion, 146–148, 
151–153
eucapnic voluntary hyperpnea (EVH), 
99, 103, 104, 113, 114, 115
exercise-associated asthma, 113, 114, 
115
forced vital capacity (FVC)
and COPD, 28
spirometry, 13–14
functional residual capacity (FRC), 38,
79, 80, 86
FVC. See forced vital capacity (FVC)
FVC borderline, 145–146
Global Lung Initiative, 2
Hx of childhood asthma, 107
hyper-reactive airways, 21
inspiratory/expiratory muscle
dysfunction, 81, 82
inspiratory muscle weakness, 82, 132
inspiratory vital capacity (IVC), 119
interpretation
clinical question in referral, 8
comparison, 5–8
CR, 5–8
detected abnormality classification,
4–5
normality/abnormality, 3–4
pattern of abnormality, 4–5
reference values, assessment, 2–3
severity of abnormality, 5, 6f
test validity, 1–2
IVC. See inspiratory vital capacity 
(IVC)
LLN. See lower limits of normal (LLN)
lower limits of normal (LLN), 3–4
maximal expiratory pressure
(Pmax/MEP), 79, 80
maximal inspiratory pressure 
(Pmax/MIP), 79, 80
mean predicted value (MPV), 3
mild asthma, 151–153
mitral valve repair, 92–93
motor neuron disease, probable, 
131–133
Index

167

Index

myopathy, 153–155
myotonic dystrophy, 86

cough, 111
normality/abnormality, determining. See also interpretation
LLN, 3–4
MPV, 3
normal range, definition, 3–4
RSD, 3
ULN, 3

paroxysmal shortness of breath, 105–106
PD. See provoking dose (PD)
P_{E_{\text{max}}}/MEP. See maximal expiratory pressure (P_{E_{\text{max}}}/MEP)
phrenic nerve damage, 92–93
P_{I_{\text{max}}}/MIP. See maximal inspiratory pressure (P_{I_{\text{max}}}/MIP)
pneumonia, 129–130, 136–137
polymyositis, 88–89
post-BSLTx, 153–155
provoking dose (PD), 100
pulmonary hypertension, 149–151

quality tests
assessment, 117, 119, 120
factors, 117, 118
rating scales, 117, 118
spirometry, 118
suboptimal, 119–120
asthma, 122–123, 134–137
chronic cough, 124–125
lung mass, baseline spirometry, 121
pneumonia, 129–130, 136–137
probable motor neuron disease, 131–133

report writing, features
subjectivity, 10–11
technical interpretation vs. clinical context, 9–10
residual standard deviation (RSD), 3
respiratory muscle impairment, 131–133

respiratory muscle strength
amyloid myopathy, 87–88
breathlessness, 96–97
cough and dyspnoea, 92–93
measurement, 79, 83
myotonic dystrophy, 86
normal range limits, 81–82
parameters, interpretation, 81
polymyositis, 88–89
right diaphragm paralysis, 84–85
SLE, 90–92
steps, interpretation, 84
test quality, 80
reversible obstructive airways disease, 151–153
RSD. See residual standard deviation (RSD)
scleroderma, 149–151
scoliosis, 149–151
severe systemic lupus erythematosus (SLE), 90–92
slow vital capacity (SVC), 119
SLV. See static lung volume (SLV)
sniff nasal inspiratory pressure (sNIP), 79–82, 87, 88, 95

spirometry
asthma, 23–24, 26–27, 32–34
baseline, 9, 18, 23, 34, 44, 45, 46, 48, 50, 62, 67, 69, 76, 100, 106, 121, 128, 135, 144, 157, 159
BD. see bronchodilator (BD)
bronchiectasis, 25–26
cancer, trachea, 30
comparsions, 19
COPD, 24–25, 28
FVC borderline, 145–146
hyper-reactive airways, 21
ILD, 31
lung pathology, 15
obstructive ventilatory defects, 16, 171
pre-surgical assessment, 22
primary parameters, 13, 14
quality rating scale, 118
restriction, 142–145
restrictive ventilatory defect, 29–30
shape, flow–volume curve, 18–19
spirometry (continued)
interpretation, 17, 17f, 21
TLC, 15, 16
tracheomalacia, 35
upper airway obstruction, 20–21, 20f
ventilatory function patterns, 15, 16f
vocal cord pathology, 36
static lung volume (SLV)
application, 41
asthma, 44–45
cardiomyopathy, respiratory assessment, 43–44
comparisons, 40–41
COPD, 41–42, 49–52
interstitial lung disease, HRCT, 46–47
non-specific ventilatory pattern, 39, 40
obesity hypoventilation syndrome, 48–49
parameters, 38
plethysmography, 37
sarcoidosis, 47–48
test quality, 37–38
and TLC, 59
ULN, 38–39, 39f, 40f
ventilatory function, spirometry and TLC, 39, 40
washout and dilution methods, 37
SVC. See slow vital capacity (SVC)
TLC. See total lung capacity (TLC)
total lung capacity (TLC)
and FVC, 16
morbid obesity, 49
neuromuscular disease, 57
reduced, 82
and SLV, 59
spirometry, 39
static lung volume measured, 15–16
and ULN, 38
ULN. See upper limit of normal (ULN)
upper airway obstruction, 20–21
upper limit of normal (ULN), 3, 38–39, 43
vasculitis, 139–142
wheeze, 111, 112, 158–159